[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caredx Inc (CDNA)

Caredx Inc (CDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,982,156
  • Shares Outstanding, K 51,659
  • Annual Sales, $ 379,810 K
  • Annual Income, $ -21,350 K
  • EBIT $ -16 M
  • EBITDA $ 5 M
  • 60-Month Beta 2.43
  • Price/Sales 5.40
  • Price/Cash Flow N/A
  • Price/Book 6.55

Options Overview Details

View History
  • Implied Volatility 66.50% (-8.33%)
  • Historical Volatility 100.08%
  • IV Percentile 8%
  • IV Rank 13.87%
  • IV High 224.22% on 03/10/26
  • IV Low 41.09% on 05/14/26
  • Expected Move (DTE 31) 4.94 (12.77%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 30
  • Volume Avg (30-Day) 310
  • Put/Call OI Ratio 4.02
  • Today's Open Interest 5,118
  • Open Int (30-Day) 1,526
  • Expected Range 33.73 to 43.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +624,475.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.50 +58.22%
on 06/23/26
40.47 -4.21%
on 07/17/26
+12.58 (+48.07%)
since 06/18/26
3-Month
18.15 +113.58%
on 04/29/26
40.47 -4.21%
on 07/17/26
+18.03 (+87.00%)
since 04/21/26
52-Week
11.26 +244.29%
on 08/07/25
40.47 -4.21%
on 07/17/26
+26.01 (+204.04%)
since 07/21/25

Most Recent Stories

More News
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter...

CDNA : 38.88 (+1.33%)
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

CDNA : 38.88 (+1.33%)
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

NavDx ® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market...

CDNA : 38.88 (+1.33%)
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions

CDNA : 38.88 (+1.33%)
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

Growing body of evidence supports AlloSure ® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes Data across...

CDNA : 38.88 (+1.33%)
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

AlloSure ® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data...

CDNA : 38.88 (+1.33%)
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant...

CDNA : 38.88 (+1.33%)
CareDx to Participate in Upcoming Investor Conferences

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...

CDNA : 38.88 (+1.33%)
CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...

CDNA : 38.88 (+1.33%)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...

CDNA : 38.88 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

3rd Resistance Point 41.27
2nd Resistance Point 40.56
1st Resistance Point 39.46
Last Price 38.90
1st Support Level 37.65
2nd Support Level 36.94
3rd Support Level 35.84

See More

52-Week High 40.47
Last Price 38.90
Fibonacci 61.8% 29.31
Fibonacci 50% 25.86
Fibonacci 38.2% 22.42
52-Week Low 11.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.